IMWG consensus: cement augmentation for myeloma VCFs
TL;DR4-8 wk window: IMWG advises offering BKP or PV for painful myeloma VCFs, with VAS ≥6 triaging to immediate augmentation and up to 3 levels per session.
CAFE
The RT boundary is explicit: RT shrinks a soft-tissue myelomatous mass but neither stabilises a VCF nor relieves bony neural compression, and prior RT or its dose does not contraindicate later cement. That narrows RT for painful myeloma VCFs to unresolved plasmacytoma, no systemic option, or posterior-element disease precluding BKP/PV, with marrow sparing as a stated aim.
In a myeloma pt with a painful, MRI-confirmed unhealed VCF and no soft-tissue canal mass, this supports cement augmentation over RT for fracture pain; it does not apply to soft-tissue cord compression, where steroids, systemic therapy and RT come first.
RT is positioned for soft-tissue mass, unresolved plasmacytoma or posterior-element disease precluding cement, not for mechanical VCF pain, since it does not stabilise the vertebra. Prior RT or its dose does not contraindicate later augmentation, so an irradiated level that stays painful remains a cement candidate.
Systemic anti-myeloma therapy is named the most important modality, with augmentation timed after 1-2 cycles when performance status, sepsis or hyperviscosity contraindicate it up front. Procedures need coordinating with the treating haematologist to avoid therapy-related anaemia, leukopaenia and thrombocytopaenia.
The panel argues against spinal metalwork in myeloma: secondary osteoporosis raises failure risk and immunosuppression raises infection risk. Cement supports the anterior and middle columns; urgent decompression is reserved for cord or cauda equina compression with deficit, or bony encroachment that steroids, chemotherapy and RT cannot reverse.
11 details
International Myeloma Working Group consensus statement updating the 2008 recommendations on vertebral cement augmentation in light of newer published data. No new patient data.
RT to be used judiciously and sparingly to spare marrow. Effective for a soft-tissue mass, not for bony compression, and does not stabilise the VCF. Prior RT and its dose are not contraindications to later PV or BKP.
CAFE is the one randomised trial cited for cancer VCFs, with only 49 MM pts. The osteoporotic sham-controlled trials (Kallmes, Buchbinder) were null for pain, which the panel attributes to excluding the sickest pts and enrolling facet-pain cases.
Systemic therapy is framed as the most important modality, with bracing to bridge the first 1-2 cycles and augmentation if fracture pain persists. Metalwork is to be avoided where possible given failure and infection risk.
VAS tiers are pragmatic triage, not validated cut points. BKP vs PV, timing relative to induction, and impending-fracture prediction are all deferred to future randomised trials.
| Tier | Panel position |
|---|---|
| Acute VCF, VAS ≥ 6 | Immediate augmentation; TLSO brace can bridge while systemic therapy starts |
| Subacute, VAS 4-6 | Chemo, bisphosphonate, analgesia first; augment if these fail or collapse risk rises |
| VAS 1-3 | Watchful surveillance with periodic imaging |
- BKP vs PV vs NSM head to head in myeloma VCFs
- Optimal timing of augmentation relative to induction therapy
- How to predict impending fracture in the myeloma spine
📚 Sources · 📄 1 paper
Abstract
The longer read
This is a panel position, and its weight depends on how much myeloma-specific evidence sits beneath it. The randomised core is CAFE, which compared BKP with non-surgical management in a mixed cancer population; only 49 of its 134 pts had myeloma, split 22 to BKP and 27 to NSM. Everything else the panel cites for myeloma is prospective single-arm or retrospective series, plus osteoporosis data. The recommendation that painful myeloma VCFs be offered BKP or PV within 4-8 weeks is therefore an extrapolation from a small randomised subset and a body of uncontrolled experience, delivered with the confidence a consensus format confers.
The panel has to contend with the two sham-controlled osteoporosis trials, Kallmes and Buchbinder, that found no pain benefit for vertebroplasty. Its rebuttal is selection: the pts most in need may have declined randomisation, and those enrolled may have had facet-mediated rather than fracture pain. That argument is plausible but untested, and it cuts both ways in myeloma. If facet pain after kyphotic deformity is common, some pts referred for cement would do as well with a facet injection, which the panel itself concedes. The insistence on MRI with STIR and T1 sequences to confirm an unhealed fracture, often with a cleft, is the practical safeguard against treating the wrong pain generator.
For a radiation oncologist the statement is a boundary-setting document. It casts RT as the right tool for a soft-tissue myelomatous mass, including cord compression without bony encroachment, and the wrong tool for mechanical fracture pain, because RT does not stabilise the vertebral body. It asks for sparing use to protect marrow and expects steroid plus novel-agent combinations to reduce palliative RT demand. That is an expectation about practice, not a measured result. The only RT comparison cited, additional kyphoplasty versus additional radiation or systemic therapy, comes from a single referenced study with no effect size in the text, so the RT-versus-cement question for myeloma VCF pain has not been tested head to head.
The most portable line is that prior RT and its dose do not contraindicate cement. It removes a common hesitation when an irradiated level stays painful, as in the illustrated case of T10 BKP after dexamethasone, RT and 2 cycles of chemotherapy. What the statement does not settle is whether BKP beats PV in myeloma, the right timing relative to induction, and how to identify an impending fracture; the panel defers all three to future randomised trials. The VAS tiers are triage conventions rather than validated thresholds, and the panel's own indications table says pain is not defined by a specific VAS number. Read it as a reasonable default pathway that clarifies where RT stops being the answer, not as evidence that cement outperforms RT for any defined myeloma population.